Title : The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.

Pub. Date : 2022 Jun

PMID : 35219776






2 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 BACKGROUND: Maintenance treatment with poly (ADP-ribose) polymerase (PARP) inhibitor is now the standard of care in patients with BRCA mutated platinum-sensitive recurrent ovarian cancer following response to chemotherapy. Platinum poly(ADP-ribose) polymerase 1 Homo sapiens
2 BACKGROUND: Maintenance treatment with poly (ADP-ribose) polymerase (PARP) inhibitor is now the standard of care in patients with BRCA mutated platinum-sensitive recurrent ovarian cancer following response to chemotherapy. Platinum poly(ADP-ribose) polymerase 1 Homo sapiens